12.1 HDFN Pathophysiology

Key Takeaways

  • HDFN is maternal IgG crossing the placenta via FcRn, coating antigen-positive fetal red cells, and triggering extravascular hemolysis in the spleen — IgM does not cause it.
  • Fetal disease is anemia that can progress to hydrops; after birth the placenta no longer clears bilirubin, so unconjugated hyperbilirubinemia can produce kernicterus.
  • ABO HDFN is usually a group O mother with an A or B infant, is often mild, can occur in a first pregnancy, and classically shows a weak or negative DAT plus spherocytes.
  • RhD HDFN is historically severe and almost always follows prior sensitization; the first antigen-positive pregnancy is usually spared unless the mother was already immunized by transfusion or an earlier pregnancy.
  • Anti-K suppresses fetal erythropoiesis on early progenitors, so titer and amniotic-fluid bilirubin underpredict anemia; also honor anti-c, anti-E, Duffy, Kidd, and anti-U.
Last updated: August 2026

12.1 HDFN Pathophysiology

Quick Answer: HDFN happens when maternal IgG crosses the placenta, coats antigen-positive fetal red cells, and triggers extravascular hemolysis. The fetus becomes anemic; severe disease produces hydrops. After birth the placenta no longer clears bilirubin, so unconjugated hyperbilirubinemia can injure the brain (kernicterus). ABO HDFN is usually mild, can hit a first pregnancy (group O mother, A or B infant), and often shows a weak or negative DAT with spherocytes. RhD HDFN is the historical severe disease and almost always follows prior sensitization. Anti-K is different again: it suppresses fetal erythropoiesis, so titer underpredicts anemia.

The June 9, 2026 BB outline parks this entire disease at III.B.3. Later sections in this chapter hand you the DAT, the eluate, Doppler, and the RhIG vial math. This section is the mechanism. If you cannot say why a first pregnancy is usually safe for anti-D but not for ABO, and why anti-K can wreck a fetus while the bilirubin looks modest, the detection and treatment items will not save you.

Only IgG crosses, and it has to find antigen

IgM does not cross the placenta. That single sentence is why naturally occurring anti-A and anti-B (mostly IgM) do not routinely destroy a group A fetus, and why a cold anti-M or anti-Le(a) is almost never an HDFN antibody. IgG is transported by the neonatal Fc receptor (FcRn) on syncytiotrophoblast. IgG1 and IgG3 cross most efficiently and are the subclasses that wreck red cells; IgG2 and IgG4 cross less well and fix complement poorly.

The antibody has to meet its antigen on the fetal red cell. Antigens that are poorly developed at birth (Lewis, I, Sd(a), Lutheran to a degree, and A and B themselves compared with adult cells) produce milder disease even when the mother has IgG. Antigens that are well developed early in fetal life (D, c, E, K, Fya, Jka, U) can produce serious disease. Kell is worse than its density on circulating cells suggests because it is already on early erythroid progenitors.

Once IgG is bound, fetal macrophages in the spleen (and to a lesser extent the liver) remove the coated cells. That is extravascular hemolysis. Intravascular lysis is not the usual HDFN picture. The fetus compensates by driving erythropoiesis: nucleated red cells spill into the circulation (erythroblastosis fetalis), the liver and spleen enlarge, and high-output cardiac failure plus hypoalbuminemia produce hydrops fetalis — ascites, pleural and pericardial effusions, skin edema, and a hydropic placenta. Untreated, the fetus dies.

After birth the problem becomes bilirubin

In utero the placenta clears unconjugated bilirubin into the mother. The anemic fetus is the emergency; jaundice is not. At delivery that clearance stops. The newborn liver has low UDP-glucuronyl transferase, so unconjugated bilirubin rises fast. Unconjugated bilirubin is lipid-soluble, crosses the blood–brain barrier, and stains basal ganglia and brainstem nucleikernicterus. Survivors can have athetoid cerebral palsy, hearing loss, and upward-gaze palsy.

So the disease has two clocks:

  • Fetal clock: anemia → hydrops → death.
  • Neonatal clock: hemolysis continues, bilirubin rises, brain is at risk.

That is why prenatal care chases MCA-PSV and hydrops, and why the newborn workup chases hemoglobin and bilirubin, not just a DAT strength. A 4+ DAT with a stable hematocrit and a modest bilirubin is not the same emergency as a weak DAT, a hemoglobin of 8 g/dL, and a climbing unconjugated bilirubin.

ABO HDFN: common, usually mild, first pregnancy allowed

ABO HDFN is almost always a group O mother with a group A or group B infant. Group O plasma contains anti-A,B with a real IgG fraction; group A and B mothers make far less IgG ABO antibody. The disease can appear in a first pregnancy because that IgG is naturally occurring — no prior transfusion or birth is required.

Why is it usually mild?

  • Fetal A and B antigens are not fully developed.
  • A and B substances in tissue and plasma adsorb a lot of the antibody before it reaches red cells.
  • The DAT is often weak or negative even when the infant is jaundiced. Do not use a negative DAT to rule out ABO HDFN in a group O mother with a jaundiced A or B neonate.
  • The smear classically shows spherocytes. Microspherocytes plus a group O mother is the ABO-HDFN postcard.
  • The dominant clinical problem is hyperbilirubinemia, not hydrops. Severe anemia and stillbirth from ABO HDFN are uncommon.

You do not titer anti-A,B for prenatal prediction. You do not give RhIG for ABO. You watch the newborn’s bilirubin and hemoglobin. Phototherapy is common; exchange is uncommon compared with historical anti-D disease.

RhD HDFN: historically severe, needs a first hit

Anti-D is an immune IgG. A D-neg woman does not have it until D+ red cells enter her circulation — a prior pregnancy, a miscarriage, or a transfusion of D+ red cells (or D+ platelets that carry residual red cells). The first antigen-positive pregnancy is usually spared because the sensitizing FMH is typically at delivery, and the primary immune response is slow and often IgM-first. The next D+ fetus meets IgG anti-D already in the mother. That is why RhIG exists, and why a history of unmatched transfusion can ruin a first pregnancy that would otherwise have been safe.

Once anti-D is present, disease can be severe. The DAT is strongly positive. Circulating cells hemolyze, nucleated red cells pour out, hydrops can appear in the second trimester, and untreated neonatal bilirubin can reach kernicterus. Before RhIG, anti-D was the leading cause of stillbirth from HDFN. It is still the antibody the exam uses as the prototype — just remember that anti-c and anti-K are the specificities that still produce a lot of real-world severe disease in countries that use RhIG well.

Anti-K and the other IgG villains

Anti-K does not play by the anti-D rulebook. Kell glycoprotein is expressed on early erythroid burst-forming and colony-forming units. Maternal anti-K can shut down fetal red-cell production. The fetus is anemic with inappropriately low reticulocytes and nucleated red cells. Amniotic-fluid bilirubin (the old Liley ΔOD450) underestimates the anemia because there is less circulating hemolysis. Titer correlates poorly with severity — a titer of 8 can hide a hydropic K+ fetus. Surveillance is MCA-PSV, and a K− father with reliable paternity lets you stand down.

Other IgG antibodies that cause HDFN and must be honored:

  • Anti-c — after anti-D, one of the most dangerous Rh antibodies; c is common, so most partners are c+.
  • Anti-E — can be mild or severe; often travels with anti-c.
  • Anti-Fya (and less often anti-Fyb) — IgG, clinically significant, enzyme-destroyed on the panel but fully able to cause HDFN.
  • Anti-Jka / anti-Jkb — can cause HDFN, usually less severe than anti-D or anti-K, but never call Kidd insignificant.
  • Anti-U, anti-s, anti-S — IgG MNS antibodies; anti-U is a high-prevalence problem in S−s−U− mothers of African ancestry and can be severe.
  • Anti-k, anti-Kpb, anti-Jsb, anti-PP1Pk — rare-donor, high-prevalence antibodies that can destroy a fetus.

Antibodies that essentially do not cause HDFN: Lewis (not on fetal red cells in meaningful amount), I (i is the cord antigen), P1, most anti-M/N unless they are IgG and reactive at 37 °C, and HTLA antibodies. Do not titer anti-Le(a).

First pregnancy is not a magic shield

Write this on the inside of your skull:

  • Alloimmune RhD, c, E, K, Duffy, Kidd, U: first pregnancy is usually safe unless the woman was already immunized by transfusion, a prior unrecognized pregnancy, or another exposure to antigen-positive red cells. A “G1P0” stem that includes a trauma transfusion last year is not a first-hit case.
  • ABO: first pregnancy is fair game.
  • Once immunized, every subsequent antigen-positive fetus is at risk, and disease often worsens with later pregnancies.

Paternal zygosity decides the fetus. A D− woman with anti-D and an R2R2 (DcE/DcE) partner has a D+ fetus. A partner who is R1r is heterozygous; the fetus has a 50% chance of being D− and unaffected. That Punnett square is how you stop doing weekly Dopplers on a D− fetus. Chapter 5 already taught you to start HDFN squares with paternal zygosity, not with a guess from the mother’s type.

Comparison you must be able to recite

FeatureABO HDFNRhD HDFNKell HDFN
Typical mother / infantO mother; A or B infantD-neg mother; D-pos infantK-neg mother; K-pos infant
First pregnancyYes — IgG is naturally occurringUsually no — needs prior sensitizationUsually no — needs prior sensitization
DATWeak or negativeStrongly positivePositive; may be modest if few circulating cells
Newborn smearSpherocytesPolychromasia, NRBCs, anemiaFew retics/NRBCs for the degree of anemia
Dominant problemHyperbilirubinemiaAnemia + hydrops, then bilirubinMarrow suppression and anemia
TiterNot used prenatallyUseful until a critical titer, then DopplerPoorly predictive — do not wait on titer
SurveillanceNewborn Hb / biliMCA-PSV after critical titerMCA-PSV even at modest titer
PreventionNoneRhIGAvoid K+ transfusions in girls and women of childbearing potential

Exam traps

  • Calling ABO HDFN impossible in a first pregnancy. It is the one that likes first pregnancies.
  • Ruling out ABO HDFN because the DAT is negative. The DAT is allowed to be negative.
  • Treating anti-K like anti-D and waiting for a titer of 32 before you worry. Anti-K suppresses erythropoiesis; Doppler early.
  • Promising a first D-neg pregnancy is safe when the stem includes a prior D+ transfusion.
  • Titration of anti-Le(a), anti-P1, or room-temperature anti-M as if they were anti-D.
  • Forgetting anti-c and anti-U as causes of severe non-D HDFN.
Loading diagram...
HDFN mechanism: IgG in, anemia in utero, bilirubin after birth
Teaching contrast: first-pregnancy HDFN risk without prior transfusion (1 = expected, 0 = not expected)
Test Your Knowledge

Which statement correctly contrasts ABO HDFN with RhD HDFN?

A
B
C
D
Test Your Knowledge

Why can anti-K cause severe fetal anemia when the maternal titer is modest and amniotic-fluid bilirubin is unimpressive?

A
B
C
D
Test Your Knowledge

A G1P0 D-neg woman received two D+ red-cell units after trauma a year ago. At 20 weeks she has anti-D. Why was this first pregnancy not spared?

A
B
C
D